Volpara Health Technologies offers a globally used, multi-vendor suite of volumetric breast imaging products designed to improve clinical decision making and the early detection of breast cancer.

EA Fund 1, Enterprise Angels flagship fund launched in 2014 invested in Volpara (formerly Matakina), netting all EA Fund 1 investors a 2x return when the EA GP Investment Committee made the decision to selldown in May 2018.